Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.

• Status: Completed
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and efficacy of a 24 hour infusion with levosimendan in patients with acute myocardial infarction and heart failure after acute percutaneous coronary intervention (PCI) treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Oslo University Hospital
• Treatments: Simendan

Criteria

Inclusion Criteria:

• Acute ST-elevation myocardial infarction subject to acute PCI or non-ST elevation myocardial infarction subject to PCI within 72 hours after start of chest pain and:

• Revascularization by PCI,

• Signs of decreased wall-motion in at least 3 of 16 segments of the left ventricle

• Dyspnoea at rest and one of the following:

pulmonary edema, pulmonary congestion,need for CPAP or ventilator, need for IC diuretics or oliguria.

Subgroup of patients in cardiogenic shock: Systolic BP below 90 after 1 hour of volume therapy.

Exclusion Criteria:

• Age below 20 years

• Heart rate above 120 bpm

• Septic shock

• ARDS

• Creatinine >450 micromol/l

• Hepatic impairment

• Significant mechanical outlet obstruction

• Allergy against study drug medication

• Anaemia (Hb <8 g/dl)

• Pregnancy